

Correspondence

Edited by Kiriakos Xenitidis and
Colin Campbell

Contents

- Cognitive-behavioural toxicity? Reflections from Westminster
- NNT and NNH remain helpful in evidence-based medicine
- Challenges in developing feasible and cost-effective therapies for use in LMICs

Cognitive-behavioural toxicity? Reflections from Westminster

At our local journal club at the Gordon Hospital, Westminster, we recently read the excellent paper by Crawford *et al* on patient experience of negative effects of psychological treatments.¹ All present were first struck by the novelty of the concept of considering the side-effect profiles of psychological therapies – and then, a split second later, astonished by our own astonishment. As psychiatrists thinking about aetiology and treatment, we are fed and watered on the biopsychosocial model. We are also accustomed to sharing the potential benefits and problems associated with treatments we offer, but seemingly only in matters of medication. We are grateful to Crawford *et al* for bringing this ‘blind spot’ to our attention and hope their paper will help raise awareness of the simple yet fundamental observation that psychosocial interventions may also have downsides.

As the authors have acknowledged in their ‘Limitations’ section, their study is not without problems. First, we – like the authors – noted the low (19%) inclusion rate of participants relative to the original sample identified. There may well be significant differences between the characteristics of the 19% who did take part and the 81% who did not, creating considerable potential for bias. Second, with a view to excluding potential confounding, we would have liked to know a good deal more about the clinical details of the participants – their diagnoses and, in particular, what other treatments they may have been receiving.

In addition to these methodological observations, we were left with a sense that the practical applicability of the study’s findings is significantly limited by the lack of what the authors term ‘qualitative data about negative effects’. When trying to imagine ourselves drawing on the paper as part of evidence-based practice, we strongly suspected that patients would not find it helpful to be told that there is a 5.23% chance they will have ‘lasting bad effects from the treatment’. We would be keen to know more about what the authors’ ‘ongoing analysis of in-depth interviews’ has revealed in this regard.

Finally – more at the level of intrigue than critique – we were interested by two findings which appear to point in rather different directions. The first is the strikingly low rate (5.23%) of reported side-effects of therapy, with roughly 87% of respondents reporting no negative effects. Taking into account the earlier point about giving as much consideration to potential side-effects of psychological (and social!) interventions as biological ones, and considering that the efficacy of psychological therapy is, at least for some conditions, broadly similar to that of medication, the side-effect rates identified seem almost too good to be true. We wonder if this may reflect a corollary in patients of our own hitherto lack of awareness of the potential downsides

of psychological treatment. On the other hand, our eyes were caught by Table 3 of the paper, which seems to indicate that receiving a large number of sessions of psychological treatment is associated with an increased rate of side-effects. Of course, it may be that the higher number of sessions is due to increased severity and complexity of cases, in which we would expect negative experiences (perhaps interpreted as side-effects) to be more frequent. However, we cannot rule out the possibility of the phenomenon of ‘cognitive-behavioural toxicity’, which should clearly be a focus for further consideration and research.

- 1 Crawford MJ, Thana L, Farquharson L, Palmer L, Hancock E, Bassett P, et al. Patient experience of negative effects of psychological treatment: results of a national survey. *Br J Psychiatry* 2016; **208**: 260–5.

Samuel C. Yates, Psychiatry Registrar, Central and North West London NHS Foundation Trust (CNWL). Email: samuelyates@doctors.org.uk; **Mesfin Mengistu**, Trust Grade Psychiatrist.

doi: 10.1192/bjp.209.3.262

Authors’ reply: We share Yates and Mengistu’s surprise at how little attention has been given to negative effects of psychological treatments. Throughout medicine, patients are given information about potential for negative effects of treatments, so that they can make informed choices about them. The principle that people should be given information about risks as well as benefits holds true in other areas of life, such as choices that people make about investing their money. So it really is surprising that people can be referred to and take up offers of psychological treatment without being told about the potential risks of treatment.

In the past, paternalism meant that people could be given treatments in the belief that these were ‘in the patient’s best interests’. However, this approach is no longer acceptable when discussing pharmacological treatments, and we believe it is no more acceptable when discussing talking treatments.

As Yates and Mengistu point out, the low response rate to this national survey means that the data do not provide a reliable estimate of how often people experience harm from psychological treatments. Ongoing research by the study team and others will hopefully ensure that a clearer picture of the features, prevalence and risk factors for the negative effects of psychotherapy will emerge, allowing strategies to be developed that reduce these effects. Only then will patients be able to provide fully informed consent for the psychological treatments that may help their condition.

Mike J. Crawford, Professor of Mental Health Research, Imperial College London. Email: m.crawford@imperial.ac.uk; **Lavanya Thana**, Research Associate

doi: 10.1192/bjp.209.3.262a

NNT and NNH remain helpful in evidence-based medicine

We read with interest the commentary by Roose *et al* regarding number needed to treat (NNT) and the concern that this metric is difficult to interpret given the high placebo response rates observed in contemporary clinical trials.¹ The principal objection of Roose and colleagues is that ‘NNTs derived from clinical trials are not directly relevant to clinical decision-making, because they are based on control conditions that do not exist in standard practice’. Although we agree that this can limit the utility of NNTs from some studies, we contend that NNTs commonly remain ‘indirectly’ relevant, as explained below.

Indirect comparisons of effect sizes among different medication choices can be quite helpful in ranking interventions for both